Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Total Eye Care PA

Neither a doctor nor a teaching hospital

Research payments

$6,944,925

668 payments

Through program year 2025, Total Eye Care PA is reported as receiving $6,944,925 in research payments, across 668 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $222,404 15
2024 Research $889,707 15
2023 Research $63,113 90
2022 Research $1,533,319 27
2021 Research $1,770,895 184
2020 Research $1,211,437 269
2019 Research $1,254,049 68

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $2,321,056 13 payments
  2. Allergan Inc. $1,865,479 32 payments
  3. Dompe Farmaceutici S.p.A. $1,032,009 22 payments
  4. AbbVie, Inc. $534,842 23 payments
  5. Bausch Health US, LLC $490,099 30 payments
  6. Alcon Research LLC $360,375 504 payments
  7. Kala Pharmaceuticals, Inc. $191,220 13 payments
  8. Aerie Pharmaceuticals, Inc. $113,300 14 payments
  9. Johnson & Johnson Vision Care, Inc. $32,447 14 payments
  10. Ocular Therapeutix, Inc. $2,500 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Multicenter Double Masked Randomized Vehicle-Controlled Parallel-Group study of AGN-190584 for Participants with Presbyopia $1,506,892 10 payments
  2. A 4-Week, Phase II, Multicenter, Randomized, Double-Masked, Vehicle- Controlled, Parallel Group Study With 4 Weeks of Follow-Up to Evaluate Safety and Efficacy of a new formulation of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution at two different Concentrations in patients with Dry Eye Disease (REDUCO) $1,031,517 19 payments
  3. A Randomized, Placebo-Controlled, Double-Masked, Multi-Center, Dose-Ranging Study to Evaluate the Safety, and Efficacy of Unr844 in Subjects With Presbyopia $792,001 2 payments
  4. A Randomized, Double-Masked, Multicenter Study to Evaluate the Safety and Efficacy of Ecf843 VS Vehicle in Subjects With Dry Eye Disease $514,768 2 payments
  5. A Prospective Study to Evaluate the Clinical Characteristics and Disease Progression of Patients With Meibomian Gland Dysfunction (MGD) $417,181 4 payments
  6. A 12-Week Parallel Group, Randomized, Placebo-Controlled, Double-Blinded, Multi-Center Study to Evaluate Efficacy and Safety of 2 Concentrations of Saf312 Eye Drops (5 MG/ML and 15 MG/ML) Used Twice-Daily in the Treatment of Post-Operative Corneal Induced $324,469 1 payment
  7. A Phase 3, Multi-Center, Randomized, Double- Masked, Saline-Controlled Trial to Evaluate the Effect of NOV03 (Perfluorohexyloctane) on Signs and Symptoms of Dry Eye Disease Associated with Meibomian Gland Dysfunction (GOBI) $285,930 7 payments
  8. Phase II Study Unr844 1.5% in Subjects With Presbyopia $244,754 2 payments
  9. Currently available treatments for presbyopia (old eye) include nonsurgical options (spectacles or contact lenses) and surgical options, however, each has its own risks and limitations. The purpose of this study is to evaluate how effective AGN-190584 is in treating presbyopia compared to vehicle (placebo). $194,703 3 payments
  10. Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease $191,220 13 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record